Novartis Eyeing US Market for Prexige Launch with Companion Test

A Novartis spokesperson told Pharmacogenomics Reporter last week that the company "plans to have discussions with the FDA about the specific requirements for the approval of lumiracoxib when used in conjunction with a biomarker program."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.